Exten Industries (fka BB: EXTI)

[Patricia_1]

Multicell Technologies (EXTI) overview revised 3/24/04

Once again a very big thank you to seatech3 on the EXTI thread at RB

Exten Announces Merger with MultiCell Subsidiary
New company name will be MultiCell Technologies, Inc.
http://www.sec.gov/Archives/edgar/data/811779/000108638004000013/ext8k032304exh991.htm

The Multicell Technologies, Inc. business is built around a revolutionary liver cell lines they have developed and patented. These offer many significant advantages, including they are:

1 - human (as opposed to porcine) liver cells that replicate and function without stimulating an immune response in the host, thereby providing a renewable source of cells to treat liver failure without immune-system side effects.
2 - nontumorigenic (non-cancerous, as opposed to other's cancerous human cell lines)
3 - immortalized (The ability of a genetically engineered cell line to reproduce indefinitely)
4 - fully-functional (as discovered by Pfizer & now, Roche, & as opposed to others, which aren't)
5 - readily available (as opposed to porcine, rat or human liver "slices")
6 - cost-effective (as opposed to porcine, rat or human liver "slices")

Here's an overview of what the liver does:
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12280

See what the industry is saying about EXTI's cell lines:
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=17331
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=21368

These cell lines are enabling EXTI to enter (and possibly dominate) 4 major markets - I'm listing these in the order I think they will be able to enter the respective markets, starting with the market they are already in:

1 - the $3.7 billion Hepatocyte Test Kit market through their MultiCell subsidiary. Through their world wide marketing and distribution agreement with XenoTech has these test kits on the market today, with their product launched at the ISSX Meeting beginning Oct 12, 2003 and is currently being marketed worldwide. Many expect this cell line to become the gold standard for this market.

These cell lines have been validated for this specific purpose by Pfizer - http://home.comcast.net/~dcmack2/ISSXPoster.pdf - who signed a 15 year non-exclusive license for EXTI's cell lines after the validation. This validation was confirmed and extended by Hoffman-LaRoche - http://home.comcast.net/~dcmack2/Roche.html - as well as by XenoTech http://homepage.mac.com/alandail/XenoTech2003.pdf

XenoTech saw Pfizer's presentation and from that sought out EXTI to become their manufacturer. That focus enabled us to quickly identify it as a potential breakthrough, which our evaluations verified.

Thus XenoTech sought out EXTI and did their own independent testing before signing to be their marketing partner on these cell lines for hepatocyte test kits. The product is now being marketed world wide, starting with 3 important conferences.

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031010005....
http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031030005....

Pfizer and XenoTech are also copresenting EXTI's technology on 2-11-04 here:

http://www.cbinet.com/events/HB405/day_one.html

and again here on 6-15-04:
http://www.isciencex.com/DDI-2004%20program%20FINAL.htm

and XenoTech is one of the exhibitors as well:

http://www.cbinet.com/events/HB405/Sponsors/sponsors.html

2 - the $43 billion Therapeutic Protein Production market through their MultiCell subsidiary. Being fully functional liver cells, they can generate therapeutic proteins with high yield and low cost vs. current methods and even can generate supplies where none exist today. Here are a couple of links with more on Therapeutic Proteins

http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=11379
http://www.multicelltechnologies.com/30/

and here's another potential application:
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12227

3 - the $2 billion bioartificial liver market through their Xenogenics subsidiary. Think of it as dialysis for the liver. Again, these fully functional immortalized liver cell lines give EXTI a major advantage in this market. Also, the design of the device is a major advantage as well. The Sybiol is designed with specially patented chambers which allow the cells to circulate for maximum efficiency and even longer utility, reducing costs to hospitals vs. the competition.


http://exten.com/exten2/sybiol.htm
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=11606
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12730
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=12266

4 - the $78 billion Liver Stem Cell Transplantation market. The holy grail of liver research - to be able to regenerate damaged liver tissue.

EXTI has also been expanding their independent board. Here is news of the latest new board member

http://biz.yahoo.com/bw/031124/245268_1.html

here's what he had to say

Dr. Maggio commented, "Exten Industries' cell-based toxicological and drug screening technologies address certain critical needs among pharmaceutical and biotech companies to make more accurate assessments of the likely success of new drug candidates before they are actually placed into clinical trials. This technology promises to increase the efficiency of drug discovery and save many millions of dollars by reducing the ultimate failure rate in clinical trials, benefiting both drug companies and consumers alike."

Here's his company:

http://www.cengent.com/corporate_info.html

Some more links to look at

here's a good post from Scott Brassfield of EXTI:
http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=5678

Here's the unofficial EXTI investor site:
http://exti.info/

Here's the official EXTI web site:
http://exten.com/

And here's another site with a great collection of EXTI information:
http://www.hannibalsweb.com/cgi-bin/hannibalsweb/ikonboard.cgi?s=61740b76cd8a5f990fe222ce30fd4d10;ac....


http://ragingbull.lycos.com/mboard/boards.cgi?board=EXTI&read=25672